Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interchangeability of 5-combined vaccine vs 4-combined vaccine + Hib booster in infants
jRCTs071230050Completed
- Sponsor
- KM Biologics
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine in Haemophilus influenzae type b disease (Hib), pertussis, diphtheria and 2 more (2 arms), sponsored by KM Biologics. Primary endpoint: Seropositivity rate (>= 1 µg/mL) against PRP. Started Sep 2023; status: completed.
02
Drugs
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCTs071230050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230050.